Echinomycin as a promising therapeutic agent against KSHV-related malignancies
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Echinomycin as a promising therapeutic agent against KSHV-related malignancies ; volume:16 ; number:1 ; day:4 ; month:5 ; year:2023 ; pages:1-6 ; date:12.2023
Journal of hematology & oncology ; 16, Heft 1 (4.5.2023), 1-6, 12.2023
- Urheber
-
Chen, Jungang
Lin, Zhen
Song, Jiao
Plaisance-Bonstaff, Karlie
James, Jennifer
Mu, Shengyu
Post, Steven R.
Dai, Lu
Qin, Zhiqiang
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13045-023-01441-5
- URN
-
urn:nbn:de:101:1-2023090608523528038267
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:49 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Chen, Jungang
- Lin, Zhen
- Song, Jiao
- Plaisance-Bonstaff, Karlie
- James, Jennifer
- Mu, Shengyu
- Post, Steven R.
- Dai, Lu
- Qin, Zhiqiang
- SpringerLink (Online service)
Ähnliche Objekte (12)
CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies
Combination of BCL-2 inhibitors and immunotherapy: a promising therapeutic strategy for hematological malignancies
KSHV-mediated ROS induction defines novel therapeutic targets in Kaposi's sarcoma
C60 fullerene as promising therapeutic agent for correcting and preventing skeletal muscle fatigue
A VCP modulator, KUS121, as a promising therapeutic agent for post-traumatic osteoarthritis
Metabolic reprogramming and metabolic sensors in KSHV-induced cancers and KSHV infection
Inflammasome inhibitors: promising therapeutic approaches against cancer
RFX1: a promising therapeutic arsenal against cancer
Therapeutic dendritic cell cancer vaccines in hematologic malignancies
BCL-2 as therapeutic target for hematological malignancies
Ancistrocladinium A induces apoptosis in proteasome inhibitor-resistant multiple myeloma cells: a promising therapeutic agent candidate
Concanavalin A as a promising lectin-based anti-cancer agent: the molecular mechanisms and therapeutic potential
CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies
Combination of BCL-2 inhibitors and immunotherapy: a promising therapeutic strategy for hematological malignancies
KSHV-mediated ROS induction defines novel therapeutic targets in Kaposi's sarcoma
C60 fullerene as promising therapeutic agent for correcting and preventing skeletal muscle fatigue
A VCP modulator, KUS121, as a promising therapeutic agent for post-traumatic osteoarthritis
Metabolic reprogramming and metabolic sensors in KSHV-induced cancers and KSHV infection
Inflammasome inhibitors: promising therapeutic approaches against cancer
RFX1: a promising therapeutic arsenal against cancer
Therapeutic dendritic cell cancer vaccines in hematologic malignancies
BCL-2 as therapeutic target for hematological malignancies
Ancistrocladinium A induces apoptosis in proteasome inhibitor-resistant multiple myeloma cells: a promising therapeutic agent candidate
Concanavalin A as a promising lectin-based anti-cancer agent: the molecular mechanisms and therapeutic potential
CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies
Combination of BCL-2 inhibitors and immunotherapy: a promising therapeutic strategy for hematological malignancies
KSHV-mediated ROS induction defines novel therapeutic targets in Kaposi's sarcoma
C60 fullerene as promising therapeutic agent for correcting and preventing skeletal muscle fatigue
A VCP modulator, KUS121, as a promising therapeutic agent for post-traumatic osteoarthritis
Metabolic reprogramming and metabolic sensors in KSHV-induced cancers and KSHV infection
Inflammasome inhibitors: promising therapeutic approaches against cancer
RFX1: a promising therapeutic arsenal against cancer
Therapeutic dendritic cell cancer vaccines in hematologic malignancies
BCL-2 as therapeutic target for hematological malignancies
Ancistrocladinium A induces apoptosis in proteasome inhibitor-resistant multiple myeloma cells: a promising therapeutic agent candidate